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I. PROJECT ID NUMBER, PUBLICATION  MORATORIUM INFORMATION, 
PROJECT DESCRIPTION: 
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Precedings HMP summary page. 
 
Project ID: 46333. No publication moratorium.  
 
The Human Microbiome Project seeks to explore the diversity of microbiota that resides in and 
on the human body, including the skin, in health and disease. The NIH Intramural Skin 
Microbiome Consortium (NISMC) is a trans-disciplinary group of experts engaged in the 
practice of genomics, bioinformatics, large-scale DNA sequencing, dermatology, immunology, 
allergy, infectious disease, and clinical microbiology. Atopic dermatitis (AD, “eczema”) is a 
chronic relapsing skin disorder that affects ~15% of U.S. children and is associated with $1 
billion of medical costs annually. AD is characterized by dry, itchy skin, infiltrated with immune 
cells. Colonization by Staphylococcus aureus (S. aureus) is ten-fold more common in AD 
patients and is associated with disease flares. We hypothesize that, in addition to S. aureus, AD 
may also be associated with additional microbes and/or selective shifts of commensal microbes 
that are relevant to disease progression. The NISMC seeks to define the microbiota that resides 
in and on the skin and nares of three patient groups, all of whom have eczematous lesions and 
are currently seen at the NIH Clinical Center: (1) AD patients; (2) Wiskott-Aldrich syndrome 
(WAS) patients; and (3) Hyper IgE syndrome (HIES) syndrome patients. Examination of the 
microbiome of patients with WAS or HIES syndromes, both rare immunodeficiencies, will 
advance our understanding of how an individual’s immune system shapes their cutaneous 
microbial community. We are performing a prospective longitudinal study that follows these 
groups of patient thorough the cycles of eczema flares, ascertaining clinical data and samples at 
each stage. To analyze the longitudinal samples obtained from both affected and unaffected skin 
sites, we will use an integrated approach including: (1) extensive characterization of bacterial 
diversity; (2) analysis of fungal diversity; (3) generation of whole-genome sequences of novel 
skin microbial isolates; and (4) metagenomic sequencing to assess microbial abundance and 
deduce metabolic activities. Examination of the microbial communities on affected and 
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unaffected skin of patients with eczema will yield insights into the gene-environment interactions 
relevant to these diseases.  
 
 
II. DATA QUALITY:   
 
For primary Sanger-based reads, the values for near-full length sequences include a 94.1% 
success rate, an average of 676 Q20 bases per sequence read, and a 92% read-pair success rate. 
For Roche/454 sequence reads, V1-V3, V3-5 and V6-V9 amplicons are all quality controlled to 
exclude reads that do not exactly match barcodes/molecular IDs, which are embedded in the 
primer sequences. All sequences are filtered for minimum read length and to remove 
contaminating human DNA by the NHGRI sequencing center. 
 
III. DATA ANALYSIS AND PUBLICATION PLANS:   
 
Data is analyzed with tools available within MOTHUR (DOTUR, SONS) and UniFrac.  
Chimeras are removed with ChimeraSlayer.  Samples are compared intra-personally within 
longitudinal survey and inter-personally between affected subjects and unaffected (healthy 
controls). Sequencing results are correlated with patients’ disease severity and specific affected 
status, such as performed in previous publications from this group.  For full-length 16S rRNA 
sequencing, we resolve the bacterial phylogeny to the species level when possible to further 
power the studies. We anticipating submiting for publication the initial results of these 16S 
rRNA sequencing results within the next 12 months.  
 
IV. DATA RELEASE PLAN:   
 
We recognize the importance of sharing clinical and sequencing data in a timely and unrestricted 
manner, and have written a data sharing policy that addresses the requirements set forth by the 
NIH and NHGRI. Our IRB-approved consents and microbiome sampling protocol include 
release of microbial sequences and aggregate human sequences to public databases and coded 
human sequence data to access-controlled databases. We have deposited our 16S rRNA 
sequences in Genbank, linked to our NCBI genome project page (#46333).  We have no data 
embargo for the use of these sequences by other investigators.  We have deposited into dbGaP 
(Study Accession: phs000266) subject and clinical data, linked to microbial Genbank ID 
numbers. We are putting in place bioinformatic tools to ensure that only high quality data and 
metadata are produced, and are working to provide that data to the community as rapidly as 
possible through the HMP data acquisition and coordination center (DACC) and public sequence 
databases via dbGaP, SRA and Trace Archives. 
 
Release of clinical data 
 
Clinical data are managed using the LabMatrix software package (v 3.6, BioFortis Inc.). 
LabMatrix collects, organizes, and maintains clinical and molecular research data. Labmatrix is 
used to maintain detailed subject records that include patient history, phenotypic data, and the 
results of laboratory tests. These records are linked to biorepositories that track specimen 
collection, usage, and analysis. Access to data in the Labmatrix database is regulated in a 
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HIPAA- and institutionally-compliant manner. Detailed demographic and clinical data are 
collected for each subject upon entry into the study. Each subject is assigned a unique identifier 
and each body site is assigned a unique site code and these identifiers, along with the collection 
date, uniquely identify a clinical sample. 
 
Consent is obtained to share coded information (not containing any unique identifying patient 
information) with researchers at NIH and other institutions. Consent is also obtained to provide 
this coded information in an access-controlled database. The clinical data relating to these studies 
will be submitted semi-annually to the database of Genotype and Phenotype (dbGaP) at NCBI. 
This database provides both open- and controlled-access to clinical data. Open access is typically 
granted to non-sensitive summary data. For instance, the prevalence of MRSA in different study 
populations could be considered non-sensitive since it does not reveal personally identifiable 
data. Access to genotypic or phenotypic data for a single study participant, however, would be 
access controlled. 
 
Release of metadata associated with sequence traces or other types of data 
 
Metadata are critical to the interpretation of the sequence data generated as part of the HMP. The 
Genomic Standards Consortium published standards regarding the minimum information for a 
genome sequence (Field et al. 2008), and work is ongoing to extend this to metagenomic data 
sets (Kottmann et al. 2008). Within the NISMC, we are implementing a standard set of metadata 
that will accompany reads and assemblies. Where possible, we are referencing standard 
ontologies and enforcing those ontologies using checks within the database. 
 
Intellectual Property Management Plan 
 
We adhere to the NIH’s Best Practices for the Licensing of Genomic Inventions. Software, 
biological resources, technologies, and protocols developed with funds from this award will be 
made readily available for research purposes to qualified individuals within the scientific 
community after publication. 
 
 
V. CONTACT PERSONS:  
 
Clinical questions: Research Nurse, 888-NIH-DERM 
 
Sequencing and analysis questions:  Julia Segre, National Institute of Human Genome Research, 
NIH 301-402-2314, jsegre@nhgri.nih.gov 
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